Treatment of Acute Promyelocytic Leukemia in Patients Presenting at Vancouver General Hospital from 1983 to 1992

References

• Stone R.M., Mayer R.J. The unique aspects of acute promyelocytic leukemia. J. Clin. Oncol 1990; 8: 1913–21
   PubMed Web of Science ®Google Scholar
• Warrell R.P., Jr., de The H., Wang Z.-Y., Degos L. Acute promyelocytic leukemia. N. Engl. J. Med. 1993; 329: 177–89
   PubMed Web of Science ®Google Scholar
• Rodeghiero F., Avvisati G., Castaman G., Barbui T., Mandelli F. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990; 75: 2112–7
   PubMed Web of Science ®Google Scholar
• Bernard J., Weil M., Boiron M., Jacquillat C., Flandrin G., Gemon M.-F. Acute promyelocytic leukemia: Results of treatment by daunorubicin. Blood 1973; 41: 489–96
   PubMed Web of Science ®Google Scholar
• Cordonnier C., Vernant J.P., Brun B., Heilmann M.G., Kuentz M., Bierling P., Farcet J.P., Rodet M., Duedari N., Imbert M., Jouault H., Mannoni P., Reyes F., Dreyfus B., Rochant H. Acute promyelocytic leukemia in 57 previously untreated patients. Cancer 1985; 55: 18–25
   PubMed Web of Science ®Google Scholar
• Kantarjian H.M., Keating M.J., Walters R.S., Estey E.H., McCredie K.B., Smith T.L., Dalton W.T., Jr., Cork A., Trujillo J.M., Freireich E.H. Acute promyelocytic leukemia: The MD Anderson Hospital experience. Am. J. Med. 1986; 80: 789–97
   PubMed Web of Science ®Google Scholar
• Sanz M.A., Jarque I., Martin G., Lorenzo I., Martinez J., Rafecas J., Pastor E., Sayas M.J., Sanz G., Gomis F. Acute promyelocytic leukemia: Therapy results and prognostic factors. Cancer 1988; 61: 7–13
   PubMed Web of Science ®Google Scholar
• Cunningham I., Gee T.S., Reich L.M., Kempin S.J., Naval A.N., Clarkson B.D. Acute promyelocytic leukemia: Treatment results during a decade at Memorial Hospital. Blood 1989; 73: 1116–22
   PubMed Web of Science ®Google Scholar
• Pallavicini E.B., Porta C., Anselmetti L., Viarengo G.L., Nastasi G., Notario A. Acute promyelocytic leukaemia (APL): Chemotherapy or bone marrow transplantation?. Bone Marrow Transplant. 1989; 4: 102, Suppl. 3
   PubMedGoogle Scholar
• Runde V., Aul C., Landen H., Dokekias A., Fillet G., Schneider W. Acute promyelocytic leukemia: Clinical findings and therapeutic results in 30 patients. Hamatol. Bluttransfus. 1990; 33: 346–50
   Google Scholar
• Bennett J.M., Andersen J.W., Cassileth P.A. Long term survival in acute myeloid leukemia: The Eastern Cooperative Oncology Group (ECOG) experience. Leuk. Res. 1991; 15: 223–7
   PubMed Web of Science ®Google Scholar
• Fenaux P., Tertian G., Castaigne S., Tilly H., Leverger G., Guy H., Bordessoule D., Lebley R., LeGall E., Colombat P., Tchemia F., Bauters F., Marty M. A randomized trial of amsacrine and rubidazone in 39 patients with acute promyelocytic leukemia. J. Clin. Oncol 1991; 9: 1556–61
   PubMed Web of Science ®Google Scholar
• Head D.R., Kopecky K., Hewlett J., Weick J., Ryan D., Files J., Bickers J., Foucar K., Montiel M., Fishleder A., Welborn J., Mills G., Billeter E., Willman C., Appelbaum F. Survival with cytotoxic therapy in acute promyelocytic leukemia, a SWOG report. Blood 1991; 78: 268a, Suppl. 1
   Google Scholar
• Huang M., Ye Y., Chen S., Chai J., Lu J.-X., Zhoa L., Gu L., Wang Z. Use of all trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988; 72: 567–72
   PubMed Web of Science ®Google Scholar
• Warrell R.P., Jr., Frankel S.R., Miller W.H., Jr., Scheinberg D.A., Itri L.M., Hittelman W.N., Vyas R., Andreeff M., Tafuri A., Jakubowski A., Gabrilove J., Gordon M.S., Dmitrovsky E. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N. Engl. J. Med. 1991; 324: 1385–93
   PubMed Web of Science ®Google Scholar
• Fenaux P., Castaigne S., Dombret H., Archimbaud E., Duarte M., Morel P., Lamy T., Tilly H., Guerci A., Maloisel F., Bordessoule D., Sadoun A., Tiberghien P., Fegueux N., Daniel M.T., Chomienne C., Degos L. All-transretinoic acid followed by intensive chemotherapy gives a high complete remission rate and may prolong remissions in newly diagnosed acute promyelocytic leukemia: A pilot study on 26 cases. Blood 1992; 80: 2176–81
   PubMed Web of Science ®Google Scholar
• Clift R.A., Buckner C.D., Thomas E.D., Kopecky K.J., Appelbaum F.R., Tallman M., Storb R., Sanders J., Sullivan K., Banaji M., Beatty P.S., Bensinger W., Cheever M., Deeg J., Doney K., Fefer A., Greenberg P., Hansen J.A., Hackman R., Hill R., Martin P., Meyers J., McGuffin R., Neiman P., Sale G., Shulman H., Singer J., Stewart P., Weiden P., Witherspoon R. The treatment of acute non-lymphoblastic leukemia by allogeneic marrow transplantation. Bone Marrow Transplant. 1987; 2: 243–58
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.-T., Flandrin G., Gallon D.A.G., Gralnick H.R., Sultan C. Proposals for the classification of the acute leukaemias. Br. J. Haematol. 1976; 33: 451–8
   PubMed Web of Science ®Google Scholar
• Bennett J.M., Catovsky D., Daniel M.T., Flandrin G., Galton D.A.G., Gralnick H.R., Sultan C. A variant form of hypergranular promyelocytic leukaemia(M3). Br. J. Haematol. 1980; 44: 169–70
   PubMed Web of Science ®Google Scholar
• Golomb H.M., Rowley J.D., Vardiman J.W., Testa J.R., Butler A. “Microgranular” acute promyelocytic leukemia: A distinct clinical, ultrastructural, and cytogenetic entity. Blood 1980; 55: 253–9
   PubMed Web of Science ®Google Scholar
• ISCN. “Guidelines for Cancer Cytogenetics, Supplement to An International System for Human Cytogenetic Nomenclature.”, F Mitelman. S Karger, Basel 1991, 1991
   Google Scholar
• Cheson B.D., Cassileth P.A., Head D.R., Schiffer C.A., Bennett J.M., Bloomfield C.D., Brunning R., Gale R.P., Grever M.R., Keating M.J., Sawitsky A., Stass S., Weinstein H., Woods W.G. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J. Clin. Oncol. 1990; 8: 813–9
   PubMed Web of Science ®Google Scholar
• Reece D.E., Barnett M., Bow E., Klingemann H.-G., Shepherd J., Shore T., Phillips G. High dose cytosine arabinoside (HD Ara-C), etoposide (VP-16) and daunorubicin (DNR) as initial induction and consolidation therapy for adult acute myelogenous leukemia (AML). Blood 1990; 76: 312a, Suppl. 1
   PubMedGoogle Scholar
• Tutschka P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen. Blood 1987; 70: 1382–8
   PubMed Web of Science ®Google Scholar
• Storb R., Deeg H.J., Pepe M., Appelbaum F., Anasetti C., Beatty P., Bensinger W., Berenson R., Buckner C.D., Clift R., Doney K., Longton G., Hansen J., Hill R., Loughran T., Jr., Martin P., Singer J., Sanders J., Stewart P., Sullivan K., Witherspoon R., Thomas E.D. Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukemia: Long-term follow-up of a controlled trial. Blood 1989; 73: 1729–34
   PubMed Web of Science ®Google Scholar
• Elmongy M.B., Nantel S.H., Reece D.E., Barnett M.J., Shepherd J.D., Klingemann H.-G., Sutherland H., Embree L., Phillips G.L. Autologous bone marrow transplantation (BMT) for acute myeloid leukemia (AML) using combined carboplatin (CBDCA) and busulfan (BU). A phase I/II study. Proc. Am. Soc. Clin. Oncol. 1993; 12: 312
   Google Scholar
• Yeager A.M., Kaizer H., Santos G.W., Saral R., Colvin O.M., Stuart R.K., Braine H.G., Burke P.J., Ambinder R.F., Burns W.H., Fuller D.J., Davis J.M., Karp J.E., May W.S., Rowley S.D., Sensenbrenner L.L., Vogelsang G.B., Wingard J.R. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide. N. Engl. J. Med. 1986; 315: 141–7
   PubMed Web of Science ®Google Scholar
• Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Clift R.A., Buckner C.D., Appelbaum F.R., Schoch G., Petersen F.B., Bensinger W.I., Sanders J., Sullivan K.M., Storb R., Singer J., Hansen J.A., Thomas E.D. Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia. J. Clin. Oncol. 1992; 10: 1723–9
   PubMed Web of Science ®Google Scholar
• Linker C.A., Ries C.A., Damon L.E., Rugo H.S., Wolf J.L. Autologous bone marrow transplantation for acute myeloid leukemia using busulfan plus etoposide as a preparative regimen. Blood 1993; 81: 311–8
   PubMed Web of Science ®Google Scholar
• Frankel S.R., Eardley A., Lauwers G., Weiss M., Warrell R.P., Jr. The “retinoic acid syndrome” in acute promyelocytic leukemia. Ann. Intern. Med. 1992; 117: 292–6
   PubMed Web of Science ®Google Scholar
• Fenaux P., LeDeley M.C., Castaigne S., Archimbaud E., Chomienne C., Link H., Guerci A., Duarte M., Daniel M.T., Bowen D., Huebner G., Bauters F., Fegueux N., Fey M., Sans M., Lowenberg B., Maloisel F., Auzanneau G., Sadoun A., Gardin C., Bastion Y., Ganser A., Jacky E., Dombret H., Chastang C., Degos L., the European A PL 91 Group. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. Blood 1993; 82: 3241–9
   PubMed Web of Science ®Google Scholar